IDH1 R132H

QM002, Ms

Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG1
Immunogen:Synthetic peptide of human IDH1/Isocitrate dehydrogenase
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Cytoplasmic
Kontrolle:Oligodendroglioma, diffuse astrocytoma
Synonyme:Cytosolic NADP isocitrate dehydrogenase, Cytosolic NADP-isocitrate dehydrogenase, ICDH, IDCD, IDH, IDHC, Idh1, IDHC_HUMAN, IDP, IDPC, Isocitrate dehydrogenase [NADP] cytoplasmic, Isocitrate dehydrogenase 1 (NADP+) soluble, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, PICD.
Verfügbar in folgenden Ländern:worldwide

Isocitrate dehydrogenase 1/ IDH1 is an enzyme that catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming alpha-ketoglutarate and CO2 in a two-step reaction. The IDH1 protein is localized in the cytoplasm and in peroxisomes. It is expressed in a wide range of species and also in organisms that lack a complete citric acid cycle. Gliomas are the most frequent primary CNS malignancy. The two common types of gliomas are astrocytomas and oligodendrogliomas. Three pathways of glioma development have been identified: primary glioblastomas that arise de novo without lower grade precursors, astrocytomas that start as grade II or III and then transform into secondary glioblastoma, or oligodendrogliomas that can transform into anaplastic oligodendroglioma. IDH1 R132H point mutation is shown in more than 70 % of gliomas, frequently in WHO grade II and III gliomas and secondary grade IV glioblastomas.
The antibody QM002 is highly specific for the R132H point mutation allowing a diagnosis of astrocytomas or oligodendrogliomas. The high rates of IDH1 mutations in oligodendroglial tumors make this mutation especially helpful for the differentiation of oligodendrogliomas from other tumors with clear cell appearance. IDH1 mutations have been shown to dominantly inhibit IDH1 catalytic activity. Assessment of the IDH1 status may be performed by immunohistochemical detection of the mutated protein. In cases with negative or inconclusive immunostaining result further analysis by DNA-based methods is necessary. Testing of the IDH1 status is relevant for diagnostic and prognostic considerations in primary brain tumors. Mutated tumors generally show a better prognosis.


[1] Yan H, Parson W, Jin G et al. (2009). N Engl J Med. 360:765-773.
[2] Capper D, Wei§ert S, Balss J et al. (2009). Acta Neuropathol. 118:599-601.
[3] Mardis ER, Ding L, Dooling DJ et al. (2009). N Engl J Med. 361:1058-1066.
[4] Camelo-Piragua S, Jansen M, Ganguly et al. (2010). Acta Neuropathol. 119:509-511.
[5] Horbinsky C, Kofler J, Yeaney G et al. (2011). Brain Pathol. 21(5):564-74.
[6] Preusser M, Capper D and Hartmann C (2011). Clin Neuropathol. 2011; 30(5):217-30.
[7] Philip B, Yu DX, Silvis MR et al. (2018): Cell Rep. 23(5):1553-1564.
[8] Cohen AL, Holmen SL and Colman H (2013). Curr Neurol Neurosci Rep. 13:345.